Introducing PrTMS – Personalized repetitive Transcranial Magnetic Stimulation
PrTMS has been used in patients with a wide variety of conditions, including those that may not have responded to medication in the past.
Electromagnetic fields (EMF’s) are produced by the biological activity of cells in all living things. They help cells to communicate with each other and also help regulate growth and repair of cells. Scientists have been interested in these fields for many years and, as early as 1874, conducted experiments on electrical stimulation on the cerebral cortex.
What Is Transcranial Magnetic Stimulation (TMS)?
Transcranial magnetic stimulation (TMS) utilizes externally produced electromagnetic fields to alter cell (neural) activity in areas of the brain. These fields are typically directed to specific focal areas of the brain and are thought to have primarily a superficial effect on the brain
Repetitive transcranial magnetic stimulation (rTMS)
Repetitive transcranial magnetic stimulation (rTMS) is a cutting edge and noninvasive brain stimulation technique that has successfully been used for the treatment of early-onset Alzheimer’s disease, stroke, depression (most notably refractory unipolar depression), obsessive-compulsive disorder, insomnia, autism, and many other psychiatric and neurological disorders. A study on unipolar depression by Padberg et al. found 100% improved RMT
rTMS provides a series of painless repeated electromagnetic pulses that result in a favorable modulation of brain neural activity.
- Only superficial brain structures can be stimulation due to the limitation of depth stimulation.
- Therapeutic uses for TMS include unipolar depression and obsessive-compulsive disorder.
- A study on unipolar depression by Padberg et al. found 100% improved RMT.
- A study by Nguyen & Gordon concluded that rTMS was a statistically superior and cost-effective anti-depression for patients with TRD (treatment-resistant depression).
- rTMS improved functional independence in patients with acute ischemic stroke when compared with sham participants.
- Conclusions include the basis for rTMS being introduced as early as possible with the onset of Alzheimer’s before neuronal loss disrupts cortical connections. Results show an overall improvement with the rTMS group Less impaired patients showed greater facial recognition capabilities with the additive of rTMS.
What is PrTMS?
Information below is taken off the Peak Logic site:
PrTMS incorporates an assessment of a patient’s unique brain electrical patterns to construct an image of neuronal communication activity. Qualitative and quantitative patient data are then used to create a neuromodulation treatment plan tailored specifically to that patient, which is then verified and approved by a qualified PrTMS provider.
What makes PrTMS different from TMS?
Personalized repetitive Transcranial Magnetic Stimulation (PrTMS) is TMS – but with a smarter, more sophisticated approach. Unlike conventional TMS that is one-size-fits-all, PrTMS utilizes a proprietary, patent-pending protocol to develop personalized treatment plans that customize the TMS therapy delivered to each patient – which may help patients achieve optimal results. PrTMS may be successful in treating a variety of brain health conditions.
Why personalization matters
You would not prescribe the same dose or even the same drug to every patient — even if they had the same symptoms or condition. The same should be true with TMS therapy. However, with conventional TMS, essentially the same therapy is delivered to every patient — regardless of their condition, circumstance, or degree of brainwave frequency disturbance.
Normal brainwave frequencies range from 8 to 12 hertz, with the exact number varying from individual to individual. Conventional TMS therapy often takes a one-size-fits-all approach by seeking to align patients to the average – about 10 hertz. In contrast, PrTMS therapy is designed to align brainwaves to the patient’s personal optimal frequency.
How is PrTMS therapy customized?
Patients’ brain function is evaluated regularly during the course of the treatment plan, and therapy is modified from session to session to provide each patient with optimal results.
How it works
The PrTMS therapeutic approach uses brainwave analysis through an EEG to measure a patient’s brain activity. This, combined with the patient’s self-assessed neurocognitive symptom scores, reveals a more complete picture of a patient’s brain health.
This patient-specific data is used to create a proposed treatment plan personalized to each patient’s unique brain, which is verified and approved by a qualified PrTMS provider – this customization allows the therapy to be delivered at a lower intensity than with conventional TMS treatment.
Chail,A., Kumar, Saini, R., Bhat, P.S., Srviastava, K., Chauhan, V. (2019). Transcranial magnetic stimulation, A review of its evolution and its current applications. Industrial Psychiatry Journal,27(2), 172-180. doi: 10.4103/ipj.ipj_88_18: 10.4103/ipj.ipj_88_18. https://www.industrialpsychiatry.org/article.asp?issn=0972-6748;year=2018;volume=27;issue=2;spage=172;epage=180;aulast=Chail
Sharma et al. (2020). Efficacy of low-frequency repetitive transcranial magnetic stimulation in Ischemic Stroke: A double-blind randomized controlled trial. American Congress of Rehabilitative Medicine, 2. https://www.sciencedirect.com/science/article/pii/S2590109520300021
Bagattini, C. et al. (2020). Enhancing cognitive training effects in Alzheimer’s Disease: rTMS as an add-on treatment. Brain Stimulation, 13(6), 1655-1664. https://www-clinicalkey-com.proxy.lib.fsu.edu/#!/content/playContent/1-s2.0-S1935861X20302497?returnurl=null&referrer=null
Mutz, J. et al. (2019). Modulation of neuronal circuitry subserving working memory in healthy human subjects by repetitive transcranial magnetic stimulation. Neurosci, 280(3), 167-170. https://www.bmj.com/content/364/bmj.l1079
Singh, A. et al. (2019). Personalized repetitive transcranial magnetic stimulation temporarily alters default mode network in healthy subjects. Scientific Reports. https://www.nature.com/articles/s41598-019-42067-3